Table 2 Predictors of a new ezetimibe prescription
| Â | Univariable Analysis Odds Ratio (95% CI) | Multivariable Analysis Odds Ratio (95% CI) |
|---|---|---|
Age (per year) | 0.94 (0.93 to 0.94) | 0.96 (0.95 to 0.96) |
Sex | ||
 Male | 1.01 (0.91 to 1.14) | 0.77 (0.68 to 0.86) |
 Female | Referent | Referent |
Income Quintile | Â | Â |
 Quintile 1 (lowest) | 0.86 (0.72 to 1.02) | – |
 Quintile 2 | 0.94 (0.79 to 1.12) | – |
 Quintile 3 | Referent | – |
 Quintile 4 | 1.06 (0.89 to 1.26) | – |
 Quintile 5 (highest) | 0.97 (0.81 to 1.16) | – |
Residence | ||
 Long-term care | 0.05 (0.02 to 0.14) | 0.10 (0.03 to 0.32) |
 Community | Referent | Referent |
Location of residence | ||
 Rural location | 1.13 (0.98 to 1.31) | 1.24 (1.07 to 1.44) |
 Urban | Referent | Referent |
Rostered to a family physician | ||
 Yes | 1.24 (1.07 to 1.43) | – |
 No | Referent | – |
Year of acute myocardial infarction hospitalization | 0.97 (0.95 to 0.99) | 0.96 (0.94 to 0.98) |
Hospital location | ||
 Rural hospital | 0.98 (0.84 to 1.15) | – |
 Urban | Referent | – |
Coronary artery disease | 1.07 (0.95 to 1.20) | 1.25 (1.10 to 1.42) |
Stroke | 0.75 (0.54 to 1.03) | – |
Diabetes | 0.65 (0.54 to 0.79) | – |
Peripheral vascular disease | 0.93 (0.66 to 1.30) | – |
Chronic kidney disease | 0.77 (0.64 to 0.93) | – |
Chronic dialysis | 0.52 (0.28 to 0.98) | – |
Hypertension | 0.64 (0.53 to 0.77) | – |
Liver disease | 0.95 (0.67 to 1.36) | – |
Congestive heart failure | 0.51(0.43 to 0.61) | 0.70 (0.58 to 0.85) |
Charlson comorbidity index | 0.87 (0.83 to 0.91) | 0.95 (0.91 to 1.00) |
Baseline statin use | ||
 Yes | 1.08 (0.96 to 1.21) | – |
 No | Referent | – |
Baseline statin intensity | ||
 No statin | Referent | Referent |
 High-intensity | 1.76 (1.51 to 2.06) | 1.72 (1.45 to 2.04) |
 Low-intensity | 0.73 (0.50 to 1.06) | 0.75 (0.51 to 1.09) |
 Moderate-intensity | 0.89 (0.78 to 1.02) | 0.88 (0.77 to 1.02) |
 Other intensity | 0.92 (0.46 to 1.86) | 0.94 (0.46 to 1.90) |
Post-discharge lipid test | 3.70 (3.25 to 4.20) | 3.01 (2.63 to 3.43) |
Post-discharge family physician visit within 30 days | 1.31(1.11 to 1.56) | – |
Post-discharge specialist visit within 60Â daysa | 2.35 (1.85 to 2.98) | 1.63 (1.29 to 2.08) |